Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizo-Affective Type of Psychosis Clear all
Completed Not applicable Interventional

Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy

NCT00791440
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Cognitive-Behavior Therapy, Standard Psychiatric Treatment
Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 23, 2026, 5:22 AM EDT
Suspended Not applicable Interventional

Cognitive Remediation for Coordinated Specialty Care

NCT03930251
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Clinic-Based Cognitive Remediation, Partial-Remote Cognitive Remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Brooklyn, New York • New York, New York • Queens, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

NCT00141479
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

An Integrated Program for the Treatment of First Episode of Psychosis

NCT01321177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCT00395031
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Cardiovascular Disease, Major Depressive Disorder, Psychosis NOS
Interventions
Simvastatin, Losartan
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

NCT05643196
View directory record Official record
Conditions
Schizophrenia, Schizophrenia Schizoaffective
Interventions
PLIFUS, Sham PLIFUS, MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

NCT02192593
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computer CBT
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Novel Smoking Cessation Drug for Schizophrenia

NCT02230384
View directory record Official record
Conditions
Smoking Cessation
Interventions
Active JNJ Drug, Placebo Pill
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 66 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Evaluation of mHealth for Serious Mental Illness

NCT04068467
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
Interventions
Smartphone App, Waitlist Control
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

NCT00517075
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2

NCT03896438
View directory record Official record
Conditions
Transcranial Direct Current Stimulation, Schizophrenia, Schizoaffective Disorder
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Results available

Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation

NCT00975611
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Amantadine Hydrochloride, USP, Placebo
Drug
Lead sponsor
David C. Henderson, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

NCT01242371
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Probiotic Supplement, Identical-appearing Placebo
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders

NCT02930005
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Meclofenamic acid, Pentosan polysulfate sodium
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCT01556763
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions
EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Jul 23, 2026, 5:22 AM EDT
Suspended Phase 1Phase 2 Interventional

D-serine AudRem: R33 Phase

NCT05046353
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 5:22 AM EDT
Completed No phase listed Observational

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

NCT01786369
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 5:22 AM EDT